{"id":333671,"date":"2026-10-30T15:15:24","date_gmt":"2026-10-30T09:45:24","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=333671"},"modified":"2026-10-30T15:15:24","modified_gmt":"2026-10-30T09:45:24","slug":"branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/","title":{"rendered":"3 Branded Generics and Contract Manufacturing Company, Artificial Leather Maker and Pharma Formulations Company Stocks With a Strong Future Roadmap: Innova Captab, Mayur Uniquoters and Granules India"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Innova Captab, Mayur Uniquoters and Granules India: ROE of 11.7% to 16.9% and FY22 to FY26 revenue CAGR of 9.2% to 19.5%. Prices as of 29 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three generic, synthetic leather and drug stocks to watch are Innova Captab, Mayur Uniquoters and Granules India. Their return on equity ranges from 11.7% to 16.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 19.5%. Mayur Uniquoters has the highest return on equity at 16.9%, while Innova Captab has the fastest revenue growth at 19.5% a year. Prices are based on the 29 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Generic, synthetic leather and drug stocks let investors follow companies that serve a growing part of the Indian economy. Innova Captab, Mayur Uniquoters and Granules India cover a branded generics and contract manufacturing company, an artificial leather maker and a pharma intermediates and formulations company.<\/p>\n<p>This list covers three generic, synthetic leather and drug stocks with complete current figures: Innova Captab, Mayur Uniquoters and Granules India. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#What_Are_Generic_Synthetic_Leather_and_Drug_Stocks\" title=\"What Are Generic, Synthetic Leather and Drug Stocks?\">What Are Generic, Synthetic Leather and Drug Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#Generic_Synthetic_Leather_and_Drug_Stocks_at_a_Glance\" title=\"Generic, Synthetic Leather and Drug Stocks at a Glance\">Generic, Synthetic Leather and Drug Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#Why_Do_Generic_Synthetic_Leather_and_Drug_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Generic, Synthetic Leather and Drug Stocks Have a Strong Roadmap in India?\">Why Do Generic, Synthetic Leather and Drug Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#Why_Innova_Captab_Features_Among_These_Generic_Synthetic_Leather_and_Drug_Stocks\" title=\"Why Innova Captab Features Among These Generic, Synthetic Leather and Drug Stocks\">Why Innova Captab Features Among These Generic, Synthetic Leather and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#Why_Mayur_Uniquoters_Features_Among_These_Generic_Synthetic_Leather_and_Drug_Stocks\" title=\"Why Mayur Uniquoters Features Among These Generic, Synthetic Leather and Drug Stocks\">Why Mayur Uniquoters Features Among These Generic, Synthetic Leather and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#Why_Granules_India_Features_Among_These_Generic_Synthetic_Leather_and_Drug_Stocks\" title=\"Why Granules India Features Among These Generic, Synthetic Leather and Drug Stocks\">Why Granules India Features Among These Generic, Synthetic Leather and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#Innova_Captab_vs_Mayur_Uniquoters_vs_Granules_India_on_Key_Financials\" title=\"Innova Captab vs Mayur Uniquoters vs Granules India on Key Financials\">Innova Captab vs Mayur Uniquoters vs Granules India on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#Key_Risks_to_Check_Before_Investing_in_Generic_Synthetic_Leather_and_Drug_Stocks\" title=\"Key Risks to Check Before Investing in Generic, Synthetic Leather and Drug Stocks\">Key Risks to Check Before Investing in Generic, Synthetic Leather and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#Final_Thoughts_on_Generic_Synthetic_Leather_and_Drug_Stocks\" title=\"Final Thoughts on Generic, Synthetic Leather and Drug Stocks\">Final Thoughts on Generic, Synthetic Leather and Drug Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#What_are_generic_synthetic_leather_and_drug_stocks\" title=\"What are generic, synthetic leather and drug stocks?\">What are generic, synthetic leather and drug stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#Which_generic_synthetic_leather_and_drug_stocks_are_covered_in_this_list\" title=\"Which generic, synthetic leather and drug stocks are covered in this list?\">Which generic, synthetic leather and drug stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#Why_do_generic_synthetic_leather_and_drug_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do generic, synthetic leather and drug stocks have a strong future roadmap in India?\">Why do generic, synthetic leather and drug stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#How_has_Innova_Captab_performed_financially\" title=\"How has Innova Captab performed financially?\">How has Innova Captab performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#How_has_Mayur_Uniquoters_performed_financially\" title=\"How has Mayur Uniquoters performed financially?\">How has Mayur Uniquoters performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#How_has_Granules_India_performed_financially\" title=\"How has Granules India performed financially?\">How has Granules India performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#What_risks_should_investors_check_before_buying_generic_synthetic_leather_and_drug_stocks\" title=\"What risks should investors check before buying generic, synthetic leather and drug stocks?\">What risks should investors check before buying generic, synthetic leather and drug stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/branded-generics-and-contract-manufacturing-company-artificial-leather-maker-and-pharma-formulations-company-stocks-roadmap-waymark-list\/#Is_this_list_of_generic_synthetic_leather_and_drug_stocks_investment_advice\" title=\"Is this list of generic, synthetic leather and drug stocks investment advice?\">Is this list of generic, synthetic leather and drug stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Generic_Synthetic_Leather_and_Drug_Stocks\"><\/span><strong>What Are Generic, Synthetic Leather and Drug Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Generic, synthetic leather and drug stocks are listed companies that make branded generics and manufacture for other drug brands, produce artificial leather for auto upholstery, furniture and footwear and supply intermediates and finished dosage forms to global customers. Their earnings depend on export orders, approvals and product mix.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Generic_Synthetic_Leather_and_Drug_Stocks_at_a_Glance\"><\/span><strong>Generic, Synthetic Leather and Drug Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/innovacap\/innova-captab-ltd-share-price-today\">Innova Captab<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,051.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,736<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">37.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.32<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/mayuruniq\/mayur-uniquoters-ltd-share-price-today\">Mayur Uniquoters<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">722.85<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,260<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">37.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.01<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/granules\/granules-india-ltd-share-price-today\">Granules India<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">837.35<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22,002<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.30<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Mayur Uniquoters and Granules India trade at a P\/E below the industry P\/E, while Innova Captab trades above it, which reflects the growth the market already expects. Readers comparing generic, synthetic leather and drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in generic, synthetic leather and drug stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Generic_Synthetic_Leather_and_Drug_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Generic, Synthetic Leather and Drug Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Generic, synthetic leather and drug stocks have a strong roadmap in India because steady medicine demand, vehicle makers using more synthetic upholstery and global buyers adding Indian suppliers keep widening the market for these export focused makers.<\/p>\n<ul>\n<li><strong>Contract work.<\/strong> Drug brands outsource manufacturing.<\/li>\n<li><strong>Material demand.<\/strong> Vehicles and furniture use artificial leather.<\/li>\n<li><strong>Global buyers.<\/strong> Overseas customers add Indian partners.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Innova_Captab_Features_Among_These_Generic_Synthetic_Leather_and_Drug_Stocks\"><\/span><strong>Why Innova Captab Features Among These Generic, Synthetic Leather and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the generic, synthetic leather and drug stocks on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.<\/p>\n<p>In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%.<\/p>\n<p>Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P\/E of 37.2, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.<\/p>\n<p><strong>What to watch:<\/strong> Watch the growth in the branded business and the utilisation of expanded capacity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Mayur_Uniquoters_Features_Among_These_Generic_Synthetic_Leather_and_Drug_Stocks\"><\/span><strong>Why Mayur Uniquoters Features Among These Generic, Synthetic Leather and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the pharma and material exporters shares on this list, Mayur Uniquoters is a Rajasthan-based maker of artificial leather and synthetic fabrics used in footwear, automotive upholstery, furniture and other applications.<\/p>\n<p>The company has a return on equity of 16.9%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 3,260 crore. The stock trades at a P\/E of 15.7, below the industry P\/E of 37.9.<\/p>\n<p>Revenue rose from Rs 677 crore in FY22 to Rs 1,022 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 94.4 crore in FY22 to Rs 192 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 292 crore, while net profit rose 37.8% to Rs 56.1 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company supplies automotive and footwear customers in India and overseas, and demand for synthetic leather is growing as it replaces genuine leather. A debt-free balance sheet allows it to invest in new products and capacity.<\/p>\n<p><strong>What to watch:<\/strong> Check the volume trend in automotive and footwear customers and export sales.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Granules_India_Features_Among_These_Generic_Synthetic_Leather_and_Drug_Stocks\"><\/span><strong>Why Granules India Features Among These Generic, Synthetic Leather and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.<\/p>\n<p>Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%.<\/p>\n<p>In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P\/E of 33.2, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.<\/p>\n<p><strong>What to watch:<\/strong> Monitor new product approvals and the share of finished dosages in total sales.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Innova_Captab_vs_Mayur_Uniquoters_vs_Granules_India_on_Key_Financials\"><\/span><strong>Innova Captab vs Mayur Uniquoters vs Granules India on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three generic, synthetic leather and drug stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Innova Captab<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">803<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,637<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.5%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">141<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Mayur Uniquoters<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">677<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,022<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">192<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Granules India<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,783<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,386<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.2%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">595<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.0%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Mayur Uniquoters posts the highest return on equity in this group at 16.9%. Granules India has the largest FY26 revenue at Rs 5,386 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with generic, synthetic leather and drug stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several export oriented pharma and materials stocks instead of one name, which keeps a single result from deciding the outcome.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Innova Captab<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">356<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">473<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">32.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Mayur Uniquoters<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">235<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">292<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Granules India<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,226<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,479<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.6%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Generic_Synthetic_Leather_and_Drug_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Generic, Synthetic Leather and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these generic, synthetic leather and drug stocks, the main points are: Long-term pharma and material exporters shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Currency moves.<\/strong> Export earnings move with the rupee.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter generic, synthetic leather and drug stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Generic_Synthetic_Leather_and_Drug_Stocks\"><\/span><strong>Final Thoughts on Generic, Synthetic Leather and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Generic, synthetic leather and drug stocks reward investors who follow demand trends, order books and margins together. Innova Captab, Mayur Uniquoters and Granules India each have a clear plan to grow. Based on the 29 October 2026 close, Innova Captab trades at Rs 1,051.1, Mayur Uniquoters at Rs 722.85 and Granules India at Rs 837.35. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these generic, synthetic leather and drug stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track generic, synthetic leather and drug stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_generic_synthetic_leather_and_drug_stocks\"><\/span><strong>What are generic, synthetic leather and drug stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Generic, synthetic leather and drug stocks are listed companies that make branded generics and manufacture for other drug brands, produce artificial leather for auto upholstery, furniture and footwear and supply intermediates and finished dosage forms to global customers. Their earnings depend on export orders, approvals and product mix. This list looks at three of them, Innova Captab, Mayur Uniquoters and Granules India, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_generic_synthetic_leather_and_drug_stocks_are_covered_in_this_list\"><\/span><strong>Which generic, synthetic leather and drug stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Innova Captab, Mayur Uniquoters and Granules India. Based on the 29 October 2026 close, Innova Captab traded at Rs 1,051.1, Mayur Uniquoters at Rs 722.85 and Granules India at Rs 837.35. Their return on equity ranges from 11.7% to 16.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 19.5%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_generic_synthetic_leather_and_drug_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do generic, synthetic leather and drug stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Generic, synthetic leather and drug stocks have a strong roadmap in India because steady medicine demand, vehicle makers using more synthetic upholstery and global buyers adding Indian suppliers keep widening the market for these export focused makers. The main drivers are as follows. Contract work. Drug brands outsource manufacturing. Material demand. Vehicles and furniture use artificial leather. Global buyers. Overseas customers add Indian partners. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Innova_Captab_performed_financially\"><\/span><strong>How has Innova Captab performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P\/E of 37.2, above the industry P\/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Mayur_Uniquoters_performed_financially\"><\/span><strong>How has Mayur Uniquoters performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 677 crore in FY22 to Rs 1,022 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 94.4 crore in FY22 to Rs 192 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 292 crore, while net profit rose 37.8% to Rs 56.1 crore. The company has a return on equity of 16.9%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 3,260 crore. The stock trades at a P\/E of 15.7, below the industry P\/E of 37.9. Looking ahead, the company supplies automotive and footwear customers in India and overseas, and demand for synthetic leather is growing as it replaces genuine leather. A debt-free balance sheet allows it to invest in new products and capacity.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Granules_India_performed_financially\"><\/span><strong>How has Granules India performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P\/E of 33.2, below the industry P\/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_generic_synthetic_leather_and_drug_stocks\"><\/span><strong>What risks should investors check before buying generic, synthetic leather and drug stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying generic, synthetic leather and drug stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_generic_synthetic_leather_and_drug_stocks_investment_advice\"><\/span><strong>Is this list of generic, synthetic leather and drug stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are generic, synthetic leather and drug stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Generic, synthetic leather and drug stocks are listed companies that make branded generics and manufacture for other drug brands, produce artificial leather for auto upholstery, furniture and footwear and supply intermediates and finished dosage forms to global customers. Their earnings depend on export orders, approvals and product mix. This list looks at three of them, Innova Captab, Mayur Uniquoters and Granules India, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which generic, synthetic leather and drug stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Innova Captab, Mayur Uniquoters and Granules India. Based on the 29 October 2026 close, Innova Captab traded at Rs 1,051.1, Mayur Uniquoters at Rs 722.85 and Granules India at Rs 837.35. Their return on equity ranges from 11.7% to 16.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 19.5%.\"}},{\"@type\":\"Question\",\"name\":\"Why do generic, synthetic leather and drug stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Generic, synthetic leather and drug stocks have a strong roadmap in India because steady medicine demand, vehicle makers using more synthetic upholstery and global buyers adding Indian suppliers keep widening the market for these export focused makers. The main drivers are as follows. Contract work. Drug brands outsource manufacturing. Material demand. Vehicles and furniture use artificial leather. Global buyers. Overseas customers add Indian partners. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Innova Captab performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P\/E of 37.2, above the industry P\/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.\"}},{\"@type\":\"Question\",\"name\":\"How has Mayur Uniquoters performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 677 crore in FY22 to Rs 1,022 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 94.4 crore in FY22 to Rs 192 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 292 crore, while net profit rose 37.8% to Rs 56.1 crore. The company has a return on equity of 16.9%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 3,260 crore. The stock trades at a P\/E of 15.7, below the industry P\/E of 37.9. Looking ahead, the company supplies automotive and footwear customers in India and overseas, and demand for synthetic leather is growing as it replaces genuine leather. A debt-free balance sheet allows it to invest in new products and capacity.\"}},{\"@type\":\"Question\",\"name\":\"How has Granules India performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P\/E of 33.2, below the industry P\/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying generic, synthetic leather and drug stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying generic, synthetic leather and drug stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of generic, synthetic leather and drug stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Generic, Synthetic Leather and Drug Stocks with a strong future roadmap: Innova Captab, Mayur Uniquoters and Granules India. Compare price, valuation, return on equity and revenue growth as of 28 October 2026.<\/p>\n","protected":false},"author":38,"featured_media":333670,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,18760,18710,9050,5864,11015,18759,18758],"class_list":["post-333671","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-export-oriented-pharma-and-materials-stocks","tag-generic","tag-granules-india","tag-innova-captab","tag-mayur-uniquoters","tag-pharma-and-material-exporters-shares","tag-synthetic-leather-and-drug-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["333670"],"rank_math_title":["Contract Pharma, Artificial Leather and Formulation Stocks"],"rank_math_description":["Compare 3 generic, synthetic leather and drug stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 28 Oct 2026."],"rank_math_focus_keyword":["generic, synthetic leather and drug stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-branded-generics-and-contract-manufacturing-company-artificial-leather-maker.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/333671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=333671"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/333671\/revisions"}],"predecessor-version":[{"id":333672,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/333671\/revisions\/333672"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/333670"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=333671"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=333671"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=333671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}